Drug intelligence / Profile preview

VRDN-005

Development stage: Unknown
Lead developer: Viridian Therapeutics

Overview

**VRDN-005** is a preclinical therapeutic candidate developed by Viridian Therapeutics for autoimmune disorders. It was part of the company's early discovery-stage portfolio alongside other investigational programs targeting rare and autoimmune diseases, but specific details on its modality, mechanism of action, or precise indications beyond broad autoimmune disorders have not been publicly disclosed.[3][12][13][14]

Beyond the preview

Go deeper on VRDN-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRDN-005.

Explore the full profile